Daniel Abromowitz is now at the helm as General Manager of the Spine Division for Medacta USA, a company headquartered in in Castel San Pietro, Switzerland.
Daniel Abromowitz: New GM Spine for Medacta USA
1 min read Premium comments
#medactaSecondary#danielabromowitz
The former vice president of sales and business development at Captiva Spine, Abromowitz also served as vice president of sales and marketing at Aerobiotix, Inc. As VP of sales at Xtant Medical Abromowitz managed 50 direct sales managers and sales representatives along with over 300 independent distributors. He also spent seven years as vice president of sales at X-spine Systems, Inc.
Daniel Abromowitz told OTW, “I’m thrilled to join the Medacta USA team as General Manager of the Spine Division. Looking ahead, my priorities are focused on expanding the use and adoption of our MySpine product portfolio, increasing our sales presence across the U.S. and preparing for the 9th M.O.R.E. International Symposium, which will be held April 11-13, 2019 during which Medacta International will celebrate its 20th Anniversary.”
“As a passionate supporter of collaborative worldwide innovation, Medacta International offers an incredible growth opportunity for spine in the U.S. market. My goal is to build on the successful foundation of Medacta’s joint division here in the U.S. to support our key stakeholders in spine: surgeons, patients, facilities and agents,” Abromowitz said. “By utilizing the Medacta Orthopaedic Research and Education (M.O.R.E.) Institute, Medacta surgeons are never alone. I hope to expand on these peer-to-peer training programs for spinal surgeons here in the U.S., as we build Medacta USA Spine into an innovative leader for the U.S. market.”
“Daniel is a welcomed addition to the management team, bringing an innovative management approach and broad engineering and supply chain experience,” said Eric Dremel, president of Medacta USA. “Most importantly, Daniel’s track record of sustained commercial success and relentless customer focus will allow the potential of our Spine Division to be fully realized.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.